ClinicalTrials.gg
TerminatedNCT00415246Updated Nov 22, 2019

Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer

A Phase 3 interventional study of Triptorelin (Decapeptyl®) - Treatment 8 months (pivotal study) followed by a treatment extension of 8 months (extension study) in Prostate Cancer, sponsored by Ipsen. Terminated at 31 sites in 8 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-22.

Sponsored by Ipsen · Phase 3, Interventional, and Treatment

Why this study was terminated
The preliminary data do not support the expected sustainable blood levels of triptorelin for a duration of 4 months in all patients.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing triptorelin in Prostatic Neoplasms — 6 open to participants now, 6 under way, 3 of them phase 3. triptorelin · Prostatic Neoplasms.

Planned enrollment
18th of 28
100 · median 120
Started
2006
with 1 other
Phase 3
12 of 28
2 open now
Registered
3rd of 28
by date
Lead sponsor
9 of 28
Ipsen

Among the 28 studies testing triptorelin in Prostatic Neoplasms, this one is the 18th largest by planned enrollment, is one of 2 that started in 2006, is one of 12 in phase 3, and was the 3rd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

6 of the 28 studies testing triptorelin in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About triptorelin

triptorelin: first FDA approval 2000 (TRELSTAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing triptorelin in Prostatic Neoplasms, or all of them as a file.
02

Study summary

To identify the proportion of patients remaining medically castrated (testosterone level \< 50 ng/dL) on Day 240 following two administrations of a 4-month sustained-release (SR) formulation of triptorelin.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient must give written (personally signed and dated) before completing any study-related procedure, which means any assessment or evaluation that would not have formed part of the normal medical care of the patient
  • Patient must be 18 years old or over
  • Patient must have a -confirmed diagnosis of locally advanced or prostate cancer or presenting a relapse after curative treatment which is amenable to androgen deprivation therapy
  • Patient must have an estimated survival time of greater than 8 months according to the investigator's assessment

Exclusion criteria

Exclusion Criteria:

  • Patient at risk of a serious complication in the case of tumour flare (vertebral threatening spinal cord compression or with significant obstructive uropathy)
  • Patient who underwent a previous surgical castration
  • Prostate cancer therapy within 2 months of baseline visit
  • Patient with testosterone level below 150 ng/dL at screening
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Interventions

  • DrugTriptorelin (Decapeptyl®) - Treatment 8 months (pivotal study) followed by a treatment extension of 8 months (extension study)

    Drug page: Triptorelin

06

What researchers measure

Primary outcomes

  1. Proportion of patients with testosterone serum levels maintained below the castration threshold of 50 ng/dL.

    Time frame: Day 240

Secondary outcomes

  1. Proportion of patients with testosterone serum levels maintained below the castration threshold of 50 ng/dL.

    Time frame: Day 120

  2. Proportion of patients with testosterone serum levels maintained below the castration threshold of 20 ng/dL.

    Time frame: Day 120 and 240

  3. Time to achieve castration in days post treatment (Tlag)

    Time frame: Day 35

  4. Time to escape from castration (Texit)

    Time frame: Prior 4 months

  5. Tlag and Texit confirmed by two consecutive measurements taken 1 week apart.

  6. Duration of castration in days (Tcast) Changes in PSA levels.

07

Study locations

31 sites
  • ULB Erasme
    Bruxelles, B-1070, Belgium
  • Academisch Ziekenhuis Vrije Universiteit Brussel
    Bruxelles, B-1090, Belgium
  • UCL St Luc
    Bruxelles, B-1200, Belgium
  • Universitair Ziekenhuis Antwerpen
    Edegem, B-2650, Belgium
  • UZ Gasthuisberg
    Leuven, B-3000, Belgium
  • CHU Hôpital Gabriel Montpied
    Clermont Ferrand, 63003, France
  • Hôpital Claude Huriez
    Lille, 59037, France
  • Hôpital Edouard Herriot
    Lyon, 69437, France
  • CHU Hôpital Salvator
    Marseille, 13274, France
  • Hôtel Dieu
    Nantes Cedex 1, 44093, France
  • Hôpital du Val de Grace
    Paris Cedex 05, 75230, France
  • Centre Hospitalier Saint Louis
    Paris Cedex 10, 75475, France
  • Hôpital Cochin
    Paris cedex 14, 75679, France
  • Hôpital Bichat
    Paris Cedex 18, 75788, France
  • CHU Hôpital de la Miletrie
    Poitiers, 86000, France
  • Hôpital Pontchaillou
    Rennes Cedex 9, 35033, France
  • CHU Rangueil
    Toulouse Cedex 9, 31059, France
  • Olega Hublarova arsta prakse urologija
    Daugavpils, Latvia
  • Latvijas Onkologijas centre
    Riga, Latvia
  • Paula Stradina Kliniska Universitates slimnica
    Riga, Latvia
  • Kauno Medicinos Universitteto Klinikos
    Kaunas, Lithuania
  • UAB 'Vilniaus onkourologijos-ginekologijos klinika
    Vilnius, Lithuania
  • Vilniaus universiteto
    Vilnius, Lithuania
  • Swietokrzyskie Centrum Onkologii
    Kielce, Poland
  • NZOZ Specjalista Sp, z.o.o.
    Kutno, Poland
  • Centrum Onkologii Instytut im. M. Sklodowskiej-Curie
    Warszawa, Poland
  • Akademicki Szpital Kliniczny
    Wroclaw, Poland
  • Hospital Gregorio Maranon
    Madrid, Spain
  • Ivano Frankovsk State Medical University
    Ivano-Frankivsk, Ukraine
  • Scientific Research Institute of Urology
    Kiev, Ukraine
  • Aberdeen Royal Infirmary
    Aberdeen, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2006
First posted
Dec 22, 2006
Start
Nov 2006
CompletionActual
Oct 2007
Last update
Nov 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00415246
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Dec 22, 2006
Start date
Nov 2006
Completion
Oct 2007
Last update
Nov 22, 2019

Study contacts

Ipsen Medical Director
study director · Ipsen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triptorelin

Start the discussion